In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $29.28, indicating a +1.14% shift from the previous trading day.

It's hard to overstate how much demand could be out there for effective weight management drugs. The global anti-obesity drug ...

(NYSE: FDX) had stocks drifting lower and set for another week of losses. Investors are trying to price in uncertainty regarding the Trump administration’s tariffs, which are set to go into effect on ...

Currently trading with a volume of 1,145,610, the VKTX's price is down by -1.23%, now at $28.0. RSI readings suggest the ...

Viking Therapeutics stock is down 52% over the trailing-12-month period. However, many Wall Street analysts remain ...

Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

We recently published a list of 10 Stocks Skyrocketing Today. In this article, we are going to take a look at where Viking ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern. The ...

US biopharma Viking Therapeutics developing therapies for metabolic and endocrine disorders, closed Tuesday’s trading 5% ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The ...

Viking Therapeutics remains speculative despite progress in its clinical portfolio, notably the VK2735 program for obesity.